Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25150542 | 0.85 | CCNE2 (0.41) | PTGS2PIK3CGJAK2JAK3HTR6 | |
| SCHEMBL25150800 | 0.78 | PTGS2 (0.42) | PTGS2PIK3CGJAK2JAK3HTR6 | |
| SCHEMBL23023568 | 0.74 | PTGS2 (0.41) | PTGS2PIK3CGHTR6KCNQ3KCNQ2 | |
| SCHEMBL25150770 | 0.74 | KDM5B (0.39) | PTGS2PIK3CGJAK2JAK3HTR6 | |
| SCHEMBL14712196 | 0.72 | PIK3CG (0.62) | PTGS2PIK3CGJAK2JAK3HTR6 | |
| SCHEMBL12146434 | 0.72 | PIK3CG (0.54) | PTGS2PIK3CGJAK2JAK3HTR6 | |
| SCHEMBL3707696 | 0.71 | PIK3CG (0.49) | PIK3CGJAK2JAK3FLT3PIK3CD | |
| SCHEMBL23013599 | 0.70 | PDE2A (0.41) | PTGS2KCNQ3KCNQ2 | |
| SCHEMBL21555747 | 0.70 | HTR6 (0.49) | PIK3CGJAK2JAK3HTR6KCNQ3 | |
| SCHEMBL25024696 | 0.69 | PIK3CG (0.47) | PTGS2PIK3CGJAK2JAK3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | PTGS2 3812/4885PIK3CG 4772/4885JAK2 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.